$KBR claimed 90% satisfaction on its military relocation contract—just weeks before the Department of Defense abruptly canceled it. In this episode of Sue Wall Street, we unpack the lawsuit alleging KBR misled investors, downplayed operational issues, and triggered a sudden 10% stock drop. If you follow defense contractors, government deals, or securities litigation, this one's for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$RICK is under fire after a bombshell lawsuit alleged a decade-long tax fraud scheme, complete with bribes, falsified books, and “Dance Dollars.” In this episode of Sue Wall Street, we unpack how RCI Hospitality Holdings' adult entertainment empire spiraled into a 79-count criminal indictment and a 25% stock crash. Perfect for investors, compliance pros, and anyone tracking corporate scandal in the wildest corners of Wall Street.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Marex Group $MRX faces a rare class action brought by short sellers who claim they were misled by inflated revenues, off-book intercompany trades, and hundreds of millions in misstated cash flows. In this episode of Sue Wall Street, we dissect the alleged financial illusion: from fake operating cash flow to hidden hedge fund risks and serial restatements. If you're into forensic accounting, short-selling chaos, or global finance drama this one’s for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Fortinet $FTNT hyped a historic firewall refresh, claiming it would drive $450M in revenue. But behind the scenes, nearly half the cycle had already happened—quietly and with minimal impact. In this episode of Sue Wall Street, we break down the class action lawsuit alleging Fortinet misled investors, overstated growth, and triggered a 22% stock crash. Perfect for investors, finance pros, and anyone tracking tech accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

James Hardie Industries $JHX claimed strong demand and normal inventory levels—but investors were blindsided when sales tanked and the stock dropped over 34 percent in just two days. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging misleading statements, channel stuffing, and executive-level coverups. Perfect for retail investors, legal watchers, and finance sleuths. Get deep-dive analysis, sharp commentary, and red-flag warnings.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$BAX Baxter International is under fire after its “next-gen” infusion pump allegedly caused injuries, deaths and then a 22% stock plunge. In this episode of Sue Wall Street, we unpack the class action lawsuit claiming Baxter concealed life-threatening defects in its Novum IQ pump while touting its success to investors. If you're into medical tech, shareholder rights, or corporate cover-ups, tune in.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

$MLTX MoonLake Immunotherapeutics lost nearly 90% of its stock value in one day after clinical trial results for its flagship nanobody drug disappointed investors. In this episode of Sue Wall Street, we dissect the class action lawsuit accusing MoonLake of hyping unproven biotech claims and misleading the market. If you follow biotech stocks, clinical trial risk, or Wall Street spin, don’t miss this one.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

$ATYR aTyr Pharma promised a steroid-free future with its experimental drug—but when their Phase 3 trial failed to meet its endpoint, the stock collapsed 83% in a single day. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging investors were misled by overly optimistic claims. Biotech investors, clinical trial watchers, and Wall Street skeptics—this one's a must-listen.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

$WPP told investors 2025 would be steady even “cautiously optimistic.” Then came the surprise: plummeting revenues, CEO retirement, and a trading update that sparked an 18% stock drop. In this episode of Sue Wall Street, we break down the securities class action accusing the global ad giant of misleading investors with overconfident projections. If you're into ad tech, investor risk, or corporate spin, this one's for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama.

Visit ZLK.com for more info.

Add our WhatsApp Channel.